Global Partners Back Africa's First End-to-End Multi-Vaccine Manufacturing Hub in South Africa
核心洞察
The EIB Group, European Commission, and IFC are financing Africa's first end-to-end multi-vaccine manufacturing facility in South Africa, anchored by Biovac (搜索).
The facility, expected operational by 2028, will initially produce oral cholera (搜索) vaccines and later expand to polio (搜索), pneumonia (搜索), and meningitis (搜索) vaccines, with an annual capacity of 30–40 million doses.
The project could close up to 40% of the global cholera (搜索) vaccine supply gap, with distribution through UNICEF and Gavi ensuring equitable access for low- and middle-income countries.
A landmark financing agreement is set to transform Africa's vaccine manufacturing landscape, as the European Investment Bank (搜索) (EIB) Group, the European Commission, and the International Finance Corporation (搜索) (IFC) join forces to fund the continent's first end-to-end multi-vaccine production facility in South Africa. Anchored by South African biopharmaceutical company Biovac (搜索), the initiative represents a decisive step toward strengthening vaccine sovereignty across the region.
The project is backed by a €75 million quasi-equity investment from the EIB Group, which has also catalysed an additional $20 million senior loan through the IFC, with further funding expected to be mobilised. The investment is supported by a European Commission guarantee under the Human Development Accelerator programme, part of the European Union's broader Global Gateway strategy aimed at boosting sustainable infrastructure and development partnerships worldwide.
Facility Scope and Production Capacity
The new facility, expected to be operational by 2028, will initially focus on producing oral cholera (搜索) vaccines before expanding to include vaccines for polio (搜索), pneumonia (搜索), and meningitis (搜索). Once fully functional, the plant is projected to manufacture between 30 and 40 million vaccine doses annually, significantly enhancing regional supply capacity.
The partners estimate that the facility could help close up to 40% of the global cholera (搜索) vaccine supply gap — a critical need given recurring outbreaks in vulnerable regions. Vaccines produced at the facility are expected to be distributed through global procurement mechanisms such as UNICEF and Gavi, the Vaccine Alliance, ensuring equitable access across low- and middle-income countries.
Economic and Workforce Impact
Beyond health outcomes, the project is expected to deliver substantial economic benefits, including the creation of over 340 skilled jobs and the generation of approximately 7,000 indirect jobs. The initiative will also promote technology transfer, innovation, and the development of local scientific and manufacturing expertise.
Biovac (搜索) CEO Morena Makhoana emphasised that the facility will not only ensure reliable vaccine supply but also build long-term capabilities in Africa's biotech ecosystem.
Strategic Alignment with Continental Goals
The initiative aligns with the African Union's Vision 2040, which aims to achieve 60% local vaccine production across the continent, and supports multiple UN Sustainable Development Goals, including health, industry, economic growth, and global partnerships.
EIB President Nadia Calviño highlighted that the project will help "save lives by protecting millions of children" while empowering African scientists and healthcare systems. European Commissioner Jozef Síkela described the investment as a clear example of the Global Gateway strategy in action, combining health security with economic development. IFC Regional Vice President for Africa Ethiopis Tafara added that strengthening local manufacturing is both a development imperative and a strategic move to enhance resilience against future health crises.
A Shift Toward Regional Resilience
The COVID-19 pandemic exposed deep inequities in global vaccine access, particularly in Africa, which relied heavily on imports. This project marks a decisive shift toward regional self-reliance, reducing dependency on external supply chains and improving responsiveness to health emergencies. As global health systems adapt to emerging threats, the Biovac (搜索) facility represents a new model of collaborative, investment-driven healthcare infrastructure that combines public and private sector expertise.